German China
Metastatic BAP1-deficient melanoma is the most common intraocular malignancy in adults, but it remains rare and extremely difficult to treat once it spreads.  (Source: Turun yliopisto/University of Turku)
Lab Tools

New Lab Model to Study Rare and Deadly Melanomas

Researchers have developed a new laboratory model to study rare tumors—BAP1-deficient melanomas—that are resistant to immunotherapies. The model has the potential to transform how therapies are developed for aggressive melanomas that currently have almost no effective treatment options.

Read on

Galleries